Abstract
In their article, Lauten et al1 describe very eloquently the continued dismal prognosis of patients presenting with cardiogenic shock,2 despite tremendous strides that have been made in the field of cardiovascular medicine. The patients included in the registry met the diagnosis of cardiogenic shock as per the standard definitions from the SHOCK trial and underwent standard of care treatment, including high-dose vasopressors and intra-aortic balloon pump support if considered necessary, and the decision to institute Impella LP 2.5 …
Highlights
We agree with Dr Maini in emphasizing the fact
in plasma lactate after the beginning of Impella support suggests at least partial reversal of hypoperfusion
MD Markus Ferrari, MD Department of Internal Medicine I (Cardiology, Angiology, and Pneumology) Friedrich-Schiller University
Summary
MD Department of Cardiology Academic Medical Center University of Amsterdam
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
